Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   15.9% 10.0% 10.8% 10.1% 14.2% 23.3% 14.1% 14.1%   Credit score (0-100)   13 26 22 23 14 3 16 16   Credit rating   BB BB BB BB BB B BB BB   Credit limit (kEUR)   0.0 0.0 0.0 0.0 0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kEUR)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   7.2 -1.9 -30.4 -6.0 -8,329 -44,611 0.0 0.0   EBITDA   -111 -121 -126 -94.1 -8,419 -44,619 0.0 0.0   EBIT   -111 -121 -126 -94.1 -8,419 -44,619 0.0 0.0   Pre-tax profit (PTP)   371.2 230.4 232.5 270.9 -8,098.1 -44,552.7 0.0 0.0   Net earnings   371.2 210.4 197.0 213.0 -8,089.7 -44,491.1 0.0 0.0   Pre-tax profit without non-rec. items   371 230 232 271 -8,098 -44,553 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kEUR)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   14,194 14,404 14,601 14,814 6,725 -37,767 -37,901 -37,901   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 37,764 37,901 37,901   Balance sheet total (assets)   14,201 14,412 14,612 14,822 6,733 7.6 0.0 0.0   Net Debt   -235 -5.6 -21.7 -17.1 -11.6 37,756 37,901 37,901     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   7.2 -1.9 -30.4 -6.0 -8,329 -44,611 0.0 0.0   Gross profit growth   -97.2% 0.0% -1,543.2% 80.1% -137,660.4% -435.6% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   14,201 14,412 14,612 14,822 6,733 8 0 0   Balance sheet change%   2.7% 1.5% 1.4% 1.4% -54.6% -99.9% -100.0% 0.0%   Added value   -111.4 -120.6 -125.7 -94.1 -8,418.5 -44,619.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 -2.0 -3.0 -4.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -1,544.0% 6,520.4% 413.5% 1,556.1% 101.1% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   2.7% 1.6% 1.6% 1.8% -75.1% -199.6% 0.0% 0.0%   ROI %   2.7% 1.6% 1.6% 1.8% -75.2% -199.7% 0.0% 0.0%   ROE %   2.6% 1.5% 1.4% 1.4% -75.1% -1,321.8% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   99.9% 99.9% 99.9% 100.0% 99.9% -100.0% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   211.1% 4.7% 17.2% 18.1% 0.1% -84.6% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% -100.0% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.7% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1,877.2 1,872.2 1,394.1 2,015.2 758.7 0.7 0.0 0.0   Current Ratio   1,877.2 1,872.2 1,394.1 2,015.2 758.7 0.7 0.0 0.0   Cash and cash equivalent   235.2 5.6 21.7 17.1 11.6 7.6 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   14,193.8 14,404.2 14,601.2 14,814.2 6,724.5 -2.8 -18,950.3 -18,950.3   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0